- Home
- DCOM vs OCS Comparison
DCOM vs OCS Comparison
Compare DCOM & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCOM
- OCS
- Stock Information
- Founded
- DCOM 1864
- OCS 2003
- Country
- DCOM United States
- OCS Switzerland
- Employees
- DCOM N/A
- OCS N/A
- Industry
- DCOM Major Banks
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- DCOM Finance
- OCS Health Care
- Exchange
- DCOM Nasdaq
- OCS Nasdaq
- Market Cap
- DCOM 1.2B
- OCS 956.4M
- IPO Year
- DCOM 1996
- OCS N/A
- Fundamental
- Price
- DCOM $30.55
- OCS $16.15
- Analyst Decision
- DCOM Strong Buy
- OCS Strong Buy
- Analyst Count
- DCOM 3
- OCS 4
- Target Price
- DCOM $36.50
- OCS $35.75
- AVG Volume (30 Days)
- DCOM 183.6K
- OCS 10.7K
- Earning Date
- DCOM 10-21-2025
- OCS 08-21-2025
- Dividend Yield
- DCOM 3.25%
- OCS N/A
- EPS Growth
- DCOM N/A
- OCS N/A
- EPS
- DCOM 0.87
- OCS N/A
- Revenue
- DCOM $314,165,000.00
- OCS $960,668.00
- Revenue This Year
- DCOM $52.99
- OCS $11.49
- Revenue Next Year
- DCOM $15.71
- OCS $1,784.02
- P/E Ratio
- DCOM $35.17
- OCS N/A
- Revenue Growth
- DCOM N/A
- OCS N/A
- 52 Week Low
- DCOM $23.25
- OCS $11.56
- 52 Week High
- DCOM $37.60
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- DCOM 64.63
- OCS 25.58
- Support Level
- DCOM $28.25
- OCS $17.51
- Resistance Level
- DCOM $31.04
- OCS $18.23
- Average True Range (ATR)
- DCOM 0.77
- OCS 0.41
- MACD
- DCOM 0.18
- OCS -0.18
- Stochastic Oscillator
- DCOM 83.59
- OCS 6.67
About DCOM Dime Community Bancshares Inc.
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.